Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer-Reference-Cited by-同舟云学术

Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer

Published:2024-06-27 Issue:8 Volume:24 Page:661-664
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Strusi Alessandro¹,Pinterpe Giada²,Ciccarese Chiara³,Pedone Romina Rose¹,Sarcina Michele¹,Sardaro Valeria¹,Belletto Rachele¹,Totaro Angelo⁴,Racioppi Marco¹⁴,Berardi Rossana²,Tortora Giampaolo¹³,Iacovelli Roberto¹³

Affiliation:

1. Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy

2. Clinica Oncologica e Centro Regionale di Genetica Oncologica, AOU delle Marche, Ancona, Italy

3. Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

4. Urology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2024.2370384

Reference20 articles.

1. Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer

2. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis

3. Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial.

4. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

5. CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).